Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, said, "We are pleased to report accelerating ...

(Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced the presentation of two posters at ...

Quince Therapeutics (QNCX) “announced the presentation of two posters at the 2024 International Congress for Ataxia Research (ICAR) of data from its prior Phase 3 ...

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s ...

NT-501 is an investigational ocular implant that utilizes an encapsulated cell-based delivery system to deliver continuous ciliary neurotrophic factor.

The objective of the data analysis was to evaluate treatment-emergent adverse events in patients with Ataxia-Telangiectasia treated with the company’s lead asset, EryDex, for one year compared to ...

Inhibition of CDK6 may prevent arteriovenous malformations in hereditary hemorrhagic telangiectasia by regulating endothelial ...

The global dermatology devices market is projected to reach USD 5,213.0 million by 2023 and is expected to grow significantly ...

The following is a summary of “Prevalence and outcomes of cancer and treatment-associated toxicities for patients with Ataxia Telangiectasia,” published in the November 2024 issue of Allergy and ...

Neurotech Pharmaceuticals, Inc., an innovator in sustained drug delivery for chronic retinal diseases, today announced that the U.S. Food and Drug Administration (FDA), has extended the Prescription ...

Discover a study regime that included a treatment serum, a redness-reducing moisturizer, and sunscreen that showed promising ...